Neuroimaging Reveals Shared Brain Signature Across Five Major Psychedelics

A comprehensive international mega-analysis has identified a shared neural signature, or neural fingerprint, produced by five major psychedelic drugs in the human brain. The study, published in Nature Medicine on April 6, 2026, provides new insights into how these substances reorganize brain architecture and alter consciousness.

Researchers integrated 11 independent resting-state functional magnetic resonance imaging (fMRI) datasets from five countries across three continents. The analysis focused on the effects of psilocybin, lysergic acid diethylamide (LSD), mescaline, N,N-dimethyltryptamine (DMT), and ayahuasca.

The Neural Fingerprint of Psychedelics

The analysis of more than 500 brain scans revealed that these five substances, which had not previously been analyzed together, share a common impact on brain behavior. The primary finding is a core signature characterized by increased functional connectivity between transmodal networks and unimodal networks.

Transmodal networks include the default mode, frontoparietal, and limbic networks. Unimodal networks include the visual and somatomotor systems. The study found that psychedelics increase cross-talk between these systems, effectively reorganizing the brain’s large-scale cortical organization.

the research identified altered coupling between sensorimotor networks and key subcortical regions, specifically the putamen, caudate, and thalamus, as well as the cerebellum.

Flattening the Brain’s Hierarchy

The findings suggest that psychedelic drugs disrupt the standard operational order of the brain. According to Dr. Danilo Bzdok, a senior author of the study from McGill University, the substances dissolve the common order, the usual hierarchy of brain systems.

By flattening this hierarchy, the drugs may facilitate what users describe as raw access to one’s own consciousness. This reorganization is a temporary rewiring of the brain that occurs while users experience mind-altering effects.

While the increase in cross-network connectivity was a prominent shared feature, the researchers noted that reductions in within-network functional connectivity were selective, and varied. Bayesian modeling indicated these reductions were weak-to-moderate and differed across the specific drugs used and the networks involved.

Clinical Implications and Research Context

The identification of this shared neural signature is particularly relevant as these substances are currently being investigated in clinical trials. Researchers are exploring their potential as therapies for several severe neurological and mental health conditions, including:

• Post-traumatic stress disorder (PTSD)
• Depression
• Schizophrenia

Prior to this mega-analysis, research into the acute effects of psychedelics using resting-state fMRI had often been fragmented, with different research groups producing inconsistent findings. This study sought to facilitate greater convergence by applying a uniform preprocessing pipeline and a Bayesian hierarchical modeling framework across the combined datasets.

The results demonstrate that while psychedelics reconfigure large-scale cortical organization, they also selectively engage subcortical circuitry, providing a more comprehensive map of how these drugs influence the human brain.